Skip to main content

ZURICH HEART HOUSE

The Zurich Heart House creates and communicates new knowledge in the field of cardiovascular diseases. Through its affiliation with the University of Zurich, the editorial mandate of the "European Heart Journal" and as the seat of the "Foundation for Cardiovascular Research", the Zurich Heart House is one of the most important cardiology research and education centres in Europe.

The Zurich Heart House is a place of creative knowledge exchange between researchers, scientists, clinicians, practicing physicians, lecturers and staff. As a think tank, it is intended to strengthen Zurich as a location and serve as a service centre for doctors and patients with cardiovascular diseases.

Stay up to date with all our events - subscribe to our Newsletter HERE!


Annual Report 2023*

*in German

ZHH News

Vydia

Rising stars in cardiology: Srividya Velagapudi

Congratulations to Srividya Velagapudi, PhD, senior researcher at the Center for Molecular Cardiology of the University of Zurich, for winning the Young Investigator Award in Basic Science in 2023, for her outstanding work on Sirtuin-1, and low-density lipoprotein metabolism.

Read more here (European Heart Journal (2024) 00, 1–3)!

CMM

Postgraduate Course in Cardiometabolic Medicine 2024 | Replay videos are NOW available on demand!

The video recordings of the  2024 Postgraduate Course in Cardiometabolic Medicine are now available on demand HERE!

Florian

Research Prize of the Swiss Society of Cardiology: Congratulations to Dr. Florian Wenzl!

The 2024 Research Prize of the Swiss Society of Cardiology goes to Dr. Florian Wenzl for his outstanding original research on ‘Personalised Treatment of Acute Coronary Syndromes’ and in recognition of his exemplary dedication and evolving contributions to cardiology.

Cardiology News

AI-Cardiology

The cardiologist in the age of artificial intelligence: what is left for us?

No doubt, AI will transform cardiology as it is a specialty integrating vast amounts of data on patient history, symptoms, ECGs, laboratory values, and imaging of all sorts. So, what is left for the physician?

Read full article (Cardiovascular Research (2024) 00, 1–3)

Sex-Shock

Sex-specific prediction of cardiogenic shock after acute coronary syndromes: the SEX-SHOCK score

Cardiogenic shock (CS) remains the primary cause of in-hospital death after acute coronary syndromes (ACS), with its plateauing mortality rates approaching 50%. However, its sex-specific performance remains unknown, and refined risk prediction strategies are warranted.

Read full article (European Heart Journal (2024) 00, 1–15)

PENK

Proenkephalin improves cardio-renal risk prediction in acute coronary syndromes: the KID-ACS score

Circulating proenkephalin (PENK) is a stable endogenous polypeptide with fast response to glomerular dysfunction and tubular damage. This study examined the predictive value of PENK for renal outcomes and mortality in patients with acute coronary syndrome (ACS).

Read full article (European Heart Journal (2024) 00, 1–17)